— Bio-Path Holdings, Inc. (NASDAQ: BPTH) reported a net loss of $2.2 million or $0.78 share for the third quarter of 2019, vs. $0.74 per share loss expected.
— Research and development expenses decreased to $1.4 million from $2.3 million last year
— General and administrative expenses were $0.9 million during the three-month period, up 29% from last year
— Recorded cash of $15.4 million as of September 30, 2019, compared to $1.0 million at December 31, 2018
— Net cash used in operating activities was $6.1 million during the nine-month period ended September, compared to $4.8 million last year
ADVERTISEMENT
— Recently, appointed Martina Molsbergen, chief executive officer of C14 Consulting, to the board of directors of Bio-Path